A review in JAMA Psychiatry argues that treating major depressive disorder during pregnancy should be prioritized, concluding that when the effects of medication are separated from those of depression and its consequences, accumulated evidence suggests selective serotonin reuptake inhibitors carry little or no risk for serious adverse outcomes.
The population boundary matters and is easy to lose. The Special Communication addresses patients with major depressive disorder, a diagnosed psychiatric illness, and examines both SSRIs and serotonin-norepinephrine reuptake inhibitors. It is not a statement about everyone who takes an antidepressant during pregnancy for any reason.
In the United States, 5 to 6 percent of pregnant patients are treated with SSRIs, primarily for major depressive disorder, which affects about 12 percent of pregnant patients. Psychiatric conditions are a leading cause of maternal morbidity and mortality.
The Confounding Problem at the Center of the Debate
Evaluating SSRI safety in pregnancy has always run into the same methodological wall. Observational studies compare pregnant people taking the medication against those who are not, but the two groups differ in something other than the drug: one group has depression.
Depression itself can affect fetal and infant outcomes. So when a study finds a difference between exposed and unexposed pregnancies, the finding may reflect the medication, the underlying illness, or factors that travel with the illness.
The authors write that evaluating SSRI safety during pregnancy is challenging precisely because observational studies can be confounded by the underlying illness and related factors. Their central argument is that studies addressing this confounding point toward the medication carrying little independent risk for the most serious outcomes.
Lead author Katherine Wisner, associate chief of perinatal mental health at Children's National Hospital, said that for too long, "conversations about depression treatment during pregnancy have focused narrowly on medication exposure" rather than the risks of untreated illness.
The authors also note that evidence defining the benefits of SSRI treatment in pregnancy is more limited than the evidence describing risks, though several studies show adverse effects when treatment is discontinued in patients with moderate to severe depression.
The Limits of a Review Article
This is a Special Communication—a review and position piece synthesizing existing literature, not a new clinical trial or a fresh dataset. It does not add primary evidence, and readers should weigh it as expert synthesis rather than a new experiment.
It also does not eliminate documented risks. Smaller and better-characterized concerns remain in the literature, including neonatal adaptation syndrome, which is typically mild and self-limiting, a small increase in persistent pulmonary hypertension of the newborn, and a modest increase in postpartum hemorrhage.
Paroxetine remains a recognized exception among SSRIs, carrying older data suggesting a small increase in cardiac malformations with first-trimester exposure. Clinical practice generally avoids it in pregnancy.
The authors' institutions include Children's National Hospital, George Washington University School of Medicine, the University of British Columbia, BC Children's Hospital Research Institute, Weill Cornell Medical College, Brigham and Women's Hospital, and Harvard Medical School. Conflict of interest disclosures are published with the full article.
The Decision Facing Patients and Clinicians
The review frames the choice as one requiring structured decision-making that weighs three things together: the risks of untreated or undertreated illness, the benefits of treatment, and the potential risks of SSRI exposure. Leaving any of the three out produces a distorted picture.
That framing has practical weight for anyone who becomes pregnant while taking an antidepressant. Stopping abruptly is itself a decision with consequences, and the review points to evidence of harm when treatment is discontinued in patients with moderate to severe depression.
No one should start, stop, or change a psychiatric medication during pregnancy without talking to a clinician. That conversation involves both obstetric and mental health care, and the appropriate answer depends on illness severity, treatment history, and individual circumstances. Professional bodies have moved in the same direction, with updated perinatal guidance now recommending pharmacotherapy for perinatal mood disorders rather than withholding it.
Access as Part of the Prescription
The authors also call for expanded access to maternity, child health, and psychiatric services, particularly in communities with limited care options. That is as much an access argument as a clinical one, since structured decision-making requires a clinician available to have the conversation.
Patients without a mental health provider can ask an obstetric clinician for a referral, and many health plans cover perinatal mental health care. If you are pregnant or postpartum and struggling with your mood, that is worth raising at your next appointment rather than waiting to be asked about it.
If you are having thoughts of harming yourself, you can call or text 988 to reach the Suicide and Crisis Lifeline, which is available around the clock.
Key Questions Answered
What did the review conclude? When medication effects are separated from those of depression itself, accumulated evidence suggests SSRIs carry little or no risk for serious adverse outcomes, and that treating major depressive disorder in pregnancy should be prioritized.
Who does this apply to? Pregnant patients with major depressive disorder. The review addresses the diagnosed population, not everyone taking an antidepressant during pregnancy.
Is this new research? No. It is a Special Communication, a review and position piece synthesizing existing evidence. It does not present new primary data.
Does it say SSRIs are risk-free? No. Smaller documented concerns remain, including neonatal adaptation syndrome, a small increase in persistent pulmonary hypertension of the newborn, and a modest increase in postpartum hemorrhage.
Are all SSRIs treated the same? No. Paroxetine is a recognized exception, with older data suggesting a small increase in cardiac malformations after first-trimester exposure, and practice generally avoids it in pregnancy.
Should someone stop their antidepressant if they become pregnant? Not without medical guidance. Evidence shows adverse effects when treatment stops in patients with moderate to severe depression. The decision belongs with obstetric and mental health clinicians.
Where can someone get help? Ask an obstetric clinician for a mental health referral. If you are having thoughts of harming yourself, call or text 988 for the Suicide and Crisis Lifeline.
